2012
DOI: 10.1016/j.jval.2012.08.1685 View full text |Buy / Rent full text
|
|

Abstract: in the A1cheive study. METHODS: The CORE Diabetes Model was used to make long-term projections of clinical and cost outcomes associated with a 1% HbA1c reduction based on A1chieve, a global, prospective, observational study of basal, mealtime and biphasic insulin analogs in routine clinical practice. At baseline, mean (SD) patient age was 60 (10) years, duration of diabetes 12 (5) years and HbA1c 9.2 (1.8)%. HbA1c was reduced by 1%-point from baseline in the active group relative to the control group. Life exp… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles